Lenvatinib, a multikinase inhibitor against VEGFR1-3, platelet-derived growth factor receptor-a (PDGFR-a), c-Kit, and the RET, already approved to treat several solid cancers including thyroid cancer, renal cell and hepatocellular carcinomas, has showed promising outcomes and a manageable safety profile in HNSCC treatment [213]. This evidence concerns the gene RET and thyroid gland carcinoma.